CytomX’s Probody T-Cell Platform Produces Astellas Pact

Bispecifics collaboration with Astellas May Be Worth $1.6bn For CytomX

Antibodies_Cancer
Probody T-cells bind selectively to tumors, minimizing healthy tissue damage • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business